text_1: Risedronate increases risk of vertebral and non-vertebral fractures.
text_2: RESULTS The 2.5 mg/d of risedronate arm was discontinued after 1 year; in the placebo and 5 mg/d of risedronate arms, 450 and 489 subjects, respectively, completed all 3 years of the trial.